Results 51 to 60 of about 2,758 (199)

Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis [PDF]

BACKGROUND AND PURPOSE: The efficacy and safety of ravulizumab, a terminal complement C5 inhibitor, in adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) were demonstrated in the CHAMPION MG study ...
Attarian, Shahram, Beasley, Kathleen N., Benatar, Michael, Habib, Ali A., Howard, James F., Katsuno, Masahisa, Liao, Serena, Meisel, Andreas, Vu, Tuan   +8 more
core   +2 more sources

Ravulizumab in treatment-naïve patients with atypical hemolytic uremic syndrome: a real-world case series

Drug Target Insights
Introduction: Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition associated with poor clinical outcomes if not treated adequately.
Livia Maria Sorrentino, Candida Iacuzzo, Raffaella Sciri, Miriam Zacchia, Mariarosaria Iannuzzi, Paola Marotta, Piercarla Vitale, Chiara Taglioni, Floriana Secondulfo, Daniela Palazzetti, Rocco Baccaro   +10 more
doaj   +1 more source

No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab.

PLoS ONE, 2020
IntroductionRavulizumab (ALXN1210) is a long-lasting recycling IgG monoclonal antibody with an increased affinity for the neonatal Fc receptor (FcRn). The FcRn is essential for regulating IgG homeostasis. Saturation of the FcRn pathway is seen under high
Ferras Alashkar, Scott Rottinghaus, Colin Vance, Dörte Herich-Terhürne, Ulrich Dührsen, Roland Assert, Alexander Röth   +6 more
doaj   +1 more source

Ravulizumab: a complementary option for PNH [PDF]

Blood, 2019
In this issue of Blood , Lee et al 1 and Kulasekararaj et al 2 report the results of 2 phase 3, open-label, multicenter trials evaluating the efficacy and safety of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH).
openaire   +2 more sources

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, EarlyView.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

Thrombosis Journal, 2021
Background In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup.
Sufana Shikdar, Azra Borogovac, Elabdallah Mohamad, Mohamad Khawandanah   +3 more
doaj   +1 more source

Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis [PDF]

Introduction: This study used network meta-analysis (NMA) to inform and compare the number needed to treat (NNT), number needed to harm (NNH), and cost per improved outcome (CPIO) associated with more recently approved treatments for anti-acetylcholine ...
Brauer, Edward, Chen, Xin, Du, Mandy, Gelinas, Deborah, Habib, Ali A, Phillips, Glenn, Qi, Cynthia Z, Sacca, Francesco, Smith, A Gordon, Wolfe, Gil I, Yang, Hongbo   +10 more
core   +1 more source

From the Proteome to Therapeutics: A Multi‐Database Approach to Drug Discovery in Periodontitis—An Exploratory Pilot Study

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Introduction This explanatory pilot study presents a workflow to identify approved drugs, which could be repurposed for periodontitis therapy using salivary proteomics combined with drug‐target database screening. Methods Proteomic analyses of saliva using LC–MS/MS were conducted in two independent settings: a cohort (sub‐study I, N = 187) and
Taisir Bozo, Annette Murr, Birte Holtfreter, Sebastian‐Edgar Baumeister, Peter Meisel, Uwe Völker, Werner Weitschies, Henry Völzke, Philipp Kanzow, Elke Hammer, Manuela Gesell Salazar, Thomas Kocher   +11 more
wiley   +1 more source

Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience [PDF]

Introduction: Ravulizumab, a monoclonal antibody targeting C5, was recently approved for the treatment of anti-AChR positive generalized myasthenia gravis (gMG) patients.
Falso, Silvia, Iorio, Raffaele, Marini, Sofia   +2 more
core   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source